Eli Lilly said its Foundayo obesity pill met the main goal in a late-stage study of obstructive sleep apnea. Lilly plans to file by the end of 2026 for U.S. approval of the daily pill for adults with obesity and moderate-to-severe sleep apnea.
Reporting from 2 identified publishers across this event arc.
These publishers contributed reporting to the broader event history. Not every source addresses the specific development described above.
How this brief is built: The BriefBrief correlates multiple sources into one evolving event brief, updated as new facts emerge.
Page 4 of 21908
Same format. Every time.
Continue reading — sign in or create a free account with
